GE HealthCare reported quarterly results that outpaced Wall Street's expectations, reflecting resilient demand for diagnostic and imaging systems and a one-time lift from tariff reimbursements. The medical device maker recorded net income of $561 million for the three months ended June 30, up from $486 million a year earlier, with $129 million attributable to refunds of tariffs previously collected under policies enacted during the Trump administration.
Shares reacted positively, rising about 12% in premarket trading after the results were released.
The company posted revenue of $5.30 billion for the quarter, slightly above the consensus estimate of $5.26 billion. Sales within the imaging device portfolio expanded 7.9%, while the pharmaceutical diagnostics segment grew 15.6% year over year. On an adjusted basis, earnings per share were $1.13, ahead of the LSEG-derived analyst average of $1.04.
GE HealthCare reiterated that it had maintained its annual profit forecast earlier this month when it provided preliminary second-quarter figures. Management also disclosed that adjusted core margin declined by 40 basis points compared with the prior year, which the company attributed to inflationary pressures tied to memory chips, oil and freight.
Speaking to broader operational challenges, the company noted that "Global geopolitical instability, including the conflict in the Middle East, adversely impacted our costs, supply chains, and logistics during the second quarter of 2026." That statement highlights the combination of macro-cost pressures and supply-chain disruption weighing on margins despite revenue gains.
Tariff refunds contributed materially to the bottom line. Courts have found that certain duties imposed under the previous administration were collected improperly and should be repaid, prompting companies including GE HealthCare to pursue recovery of amounts paid. For GE HealthCare, the refunds added $129 million to quarterly net income.
Market attention on device makers remains heightened after recent commentary from the hospital sector. Earlier this month, hospital operator HCA Healthcare warned about softer demand for surgical procedures and an increase in uninsured patients, trends tied in part to diminished enrollment in Affordable Care Act plans after pandemic-era subsidies ended. Despite those concerns, several medical device companies reported results that beat estimates in the quarter, and Johnson & Johnson did not report weakness in procedure volumes.
Context for investors
- GE HealthCare's top-line performance was supported by double-digit growth in pharmaceutical diagnostics and healthy gains in imaging equipment sales.
- The $129 million in tariff repayments provided a meaningful near-term boost to net income.
- Ongoing inflation in key input and logistics costs compressed adjusted margins by 40 basis points year over year.